Guixing Ma
Impact in
- Molecular Medicine top 2%
- Antibiotic Resistance in Bacteria
Papers in
-
- Metabolism, Diabetes, and Cancer 4
- Bone Metabolism and Diseases 3
-
- Tuberculosis Research and Epidemiology 4
- Co-authors
- Hongmin Zhang (8 shared papers)Huiling Cao (14 shared papers)Ashfaq Ahmad (3 shared papers)Yifan Zhu (2 shared papers)Hongyan Li (1 shared paper)Runming Wang (1 shared paper)Hongzhe Sun (1 shared paper)Patrick C. Y. Woo (1 shared paper)
In The Last Decade
Guixing Ma
21 papers receiving 671 citations
Peers
Comparison fields: 5 of 95
- Molecular Medicine 218
- Applied Microbiology and Biotechnology 20
- Rehabilitation 63
- Biomaterials 62
- Endocrinology 22
Countries citing papers authored by Guixing Ma
This map shows the geographic impact of Guixing Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guixing Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guixing Ma more than expected).
Fields of papers citing papers by Guixing Ma
This network shows the impact of papers produced by Guixing Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guixing Ma. The network helps show where Guixing Ma may publish in the future.
Co-authors
The 25 scholars most cited alongside Guixing Ma, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 188 | |
| 2 | 2022 | 104 | |
| 3 | 2022 | 68 | |
| 4 | 2016 | 66 | |
| 5 | 2018 | 66 | |
| 6 | 2019 | 43 | |
| 7 | 2020 | 20 | |
| 8 | 2024 | 19 | |
| 9 | 2023 | 17 | |
| 10 | 2024 | 15 | |
| 11 | 2024 | 14 | |
| 12 | 2023 | 10 | |
| 13 | 2018 | 10 | |
| 14 | 2018 | 8 | |
| 15 | 2023 | 7 | |
| 16 | 2020 | 7 | |
| 17 | 2023 | 6 | |
| 18 | 2023 | 3 | |
| 19 | 2024 | 2 | |
| 20 | 2025 | 1 |
About Guixing Ma
Guixing Ma is a scholar working on Molecular Biology, Infectious Diseases, Oncology, Molecular Medicine and Endocrinology, Diabetes and Metabolism, having authored 23 papers that have together received 675 indexed citations. Recurring topics across this work include Metabolism, Diabetes, and Cancer (4 papers), Tuberculosis Research and Epidemiology (4 papers), Antibiotic Resistance in Bacteria (4 papers), Mesenchymal stem cell research (3 papers), Pneumocystis jirovecii pneumonia detection and treatment (3 papers), Bone Metabolism and Diseases (3 papers), Pancreatic function and diabetes (2 papers) and MicroRNA in disease regulation (2 papers). The work is most often cited by research in Molecular Medicine (218 citations), Applied Microbiology and Biotechnology (20 citations), Rehabilitation (63 citations), Biomaterials (62 citations) and Endocrinology (22 citations). Guixing Ma has collaborated with scholars based in China, Hong Kong and Norway. Frequent co-authors include Hongmin Zhang, Huiling Cao, Ashfaq Ahmad, Yifan Zhu, Hongyan Li, Runming Wang, Hongzhe Sun, Patrick C. Y. Woo, Pak‐Leung Ho and Richard Yi-Tsun Kao. Their work appears in journals such as Cellular and Molecular Life Sciences, Acta Pharmaceutica Sinica B, Nature Communications, Molecular Therapy and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.